Vidac Pharma Holding PLC Announces First Patient Dosed in Phase‑2b Study of VDA‑1102 for High‑Risk Actinic Keratosis
Vidac Pharma Holding PLC (XETRA: T9G, ISIN GB00BM9XQ619, WKN A3DTUQ) disclosed on 23 February 2026 that the first patient has been successfully enrolled and dosed in its Phase‑2b clinical study evaluating VDA‑1102 for the treatment of high‑risk actinic keratosis (AK). The study is conducted at Centroderm GmbH in Wuppertal, Germany, following completion of regulatory requirements, importation of the investigational product, and training of the medical team.
The initiation of patient dosing marks a key milestone in Vidac’s ongoing clinical development programme for VDA‑1102, a candidate intended to address proliferative lesions associated with AK. The study aims to further characterize the high‑risk AK population and to inform the design of subsequent clinical development steps.
In related corporate disclosures, Vidac reported on 20 February 2026 a material‑transactions filing in accordance with Article 19 of the German Market Abuse Regulation (MAR). The filing detailed transactions involving Dr. Max Herzberg, a member of the Board, and provided information on the nature of the transaction, which was the sale of shares of Vidac Pharma Holding PLC.
The company’s share price on 19 February 2026 closed at €0.738. The 52‑week high for the share was €0.96 on 15 January 2026, while the 52‑week low was €0.45 on 28 December 2025. Vidac Pharma remains a holding company whose subsidiaries focus on the discovery and development of medicines for oncologic and dermatologic conditions. The latest clinical milestone reinforces the company’s strategy to progress its pipeline of dermatologic therapeutics to advanced development stages.
